The effect of entecavir on Hepatitis B virus-related cirrhosis
Abstract
Objective: To explore the efficacy of Entecavir on hepatitis B virus-related decompensated cirrhosis.
Methodology: One Hundred two cases of hepatitis B virus-related decompensated cirrhosis patients were randomly divided into treatment group (N=51) and control group (N=51). Both groups received conventional treatment, meanwhile treatment group received Entecavir for anti-virus treatment.
Results: Comparison of liver function between the two groups was statistically significant (P < 0.01) at week 4, 8 and 12 after antiviral therapy, liver fibrosis contrast of two groups was statistically significant (P < 0.01) at week 4, 8 and 12 after antiviral therapy.
Conclusions: Although Entecavir can be effective in treating hepatitis B virus-related decompensated cirrhosis, its resistance and course of treatment need to be further evaluated.
Methodology: One Hundred two cases of hepatitis B virus-related decompensated cirrhosis patients were randomly divided into treatment group (N=51) and control group (N=51). Both groups received conventional treatment, meanwhile treatment group received Entecavir for anti-virus treatment.
Results: Comparison of liver function between the two groups was statistically significant (P < 0.01) at week 4, 8 and 12 after antiviral therapy, liver fibrosis contrast of two groups was statistically significant (P < 0.01) at week 4, 8 and 12 after antiviral therapy.
Conclusions: Although Entecavir can be effective in treating hepatitis B virus-related decompensated cirrhosis, its resistance and course of treatment need to be further evaluated.
Refbacks
- There are currently no refbacks.
